| Financial toxicity is a broad term to describe the economic consequences and subjective burden resulting from a cancer diagnosis and treatment. As financial toxicity is associated with poor disease outcomes, recognition of this problem and calls for strategies to identify and support those most at risk are increasing. Men with localized prostate cancer face treatment choices including active surveillance, prostatectomy or radiotherapy. The fact that potential patient out-of-pocket costs might influence decision making has rarely been acknowledged and, overall, the risk of financial toxicity for men with localized prostate cancer remains poorly studied. This shortfall requires a work-up in the context of prostate cancer and a multidimensional framework for considering a patient's risk of financial toxicity. The major elements of this framework are direct and indirect costs, patient-specific values, expectations of possible financial burdens, and individual economic circumstances. Current data indicate that total cost patterns probably differ by treatment modality: surgery might have an increased short-term effect, whereas radiotherapy might have an increased long-term risk of financial toxicity. Specific thresholds of patient income levels or out-of-pocket costs that predict risk of financial toxicity are difficult to identify. Compared with other malignancies, prostate cancer might have a lower overall risk of financial toxicity, but persistent post-treatment urinary, bowel or sexual adverse effects are likely to increase this risk.
Prostate cancer is the most common non-cutaneous malignancy in men; in the USA, 164,690 new cases were estimated for 2018 (ref. 1 ). Nearly 80% of men are diagnosed with disease localized to the prostate 2 . For these patients, prognosis and the recommended treatment paradigm are dictated by several factors including pretreatment PSA level, extent of prostatic and extraprostatic involvement, and histological Gleason score or grade grouping 3 . Men with prostate cancer often have a choice between numerous treatment options with similar oncological outcomes but different adverse effect profiles. The broad categories include radical prostatectomy, definitive radiotherapy (external beam radiotherapy (EBRT) or brachytherapy) with or without androgen-deprivation therapy or active surveillance for appropriately selected candidates 4 .
Multiple factors influence a patient's treatment decision [5] [6] [7] [8] . Overall, a physician's specific recommendation remains the most influential driver but familial pressure can also strongly influence men to choose a particular modality. Patient perceptions of better cure rates and the avoidance of certain perceived adverse effects (for example, urinary or sexual complications) are also valued. Men who prefer prostatectomy tend to value physical removal of the cancer. Notably, a patient's potential financial responsibility as a core motivator of treatment choice is rarely mentioned, although oncologists are increasingly aware of 'financial toxicity' -a comprehensive term for patient harm caused by the direct and indirect costs of cancer treatment 9 .
The concept of financial toxicity arose from concerns that rising costs of antineoplastic agents coupled with insurers' increased cost-sharing with patients might result in negative outcomes similar to traditional treatment-associated toxicities, such as nausea or pain 9 . Oncologists must face the emerging challenge that treating cancer can come with the cost of severe economic stress. In 2009, the American Society of Clinical Oncology produced a consensus statement affirming that discussions between physicians and patients about treatment costs are a critical component of high-value oncological care 10 .
Numerous cost and cost effectiveness studies have been performed in prostate cancer. For example, a systematic review published in 2017 summarized the costs and cost effectiveness of several contemporary technological advances in prostate cancer treatment (for example, robot-assisted prostatectomy, intensity-modulated radiotherapy and proton beam radiotherapy) 11 . These studies typically considered a treatment's cost from the perspective of what is charged to an insurer or national payor, often weighed against estimated quality-adjusted
Financial toxicity
A comprehensive term for the patient harm caused by the direct and indirect costs of cancer treatment.
Payor
The private or public entities that pay for health-care services. examples include private insurance companies or a government-supported single public system (for example, the National Health Service in the UK).
Financial toxicity associated with treatment of localized prostate cancer improvements in life expectancy as a result of that treatment. These types of studies are most valuable to and most often used by policymakers. For example, the UK's National Institute for Health and Care Excellence (NICE) relies on high-quality technology assessment studies to determine which interventions will be covered by the National Health Service. But, unless patients are completely uninsured, they are very rarely responsible for the full cost of their treatment. Thus, interpreting these studies at the level of the individual patient is challenging. In this Review, financial toxicity reflects economic stress at the patient level and not necessarily at the institutional or system level. In other words, an expensive intervention from a payor's perspective might or might not cause financial toxicity depending on several patient-specific factors.
Overall, the prevalence of financial toxicity is thought to be rising owing to numerous factors, such as increasingly expensive cancer therapies, an ageing population nearing retirement and, in the USA, a changing insurance landscape that increasingly shifts cost responsibility to patients 12 . A report from 2018 investigating the large, longitudinal Health and Retirement Study used a person's utilization of personal assets following a cancer diagnosis as a proxy for financial toxicity, and found the risk to be substantial; 42% of 9.5 million individuals with newly diagnosed malignancies between 2000 and 2012 had depleted their entire life's assets 2 years after diagnosis 13 .
One of the challenges of studying financial toxicity is the breadth of factors that can influence a patient's propensity to feel economic hardship. A practical consideration when reviewing the literature is that many words can be used to define cancer's multidimensional economic effect on a patient, for example, financial or cost burden, strain, hardship, distress or stress. Further adding to the complexity, researchers have, to date, measured financial toxicity in different ways: monetary measurements (for example, out-of-pocket (OOP) costs sometimes as a share of personal income); prevalence rates of objective responses to financial strain (for example, declaration of bankruptcy, increases in debt levels, reduction in leisure spending); or subjective perceptions of financial burden and possible effects on health-related quality of life (QoL) 14 .
Oncologists' heightened awareness of the problem is probably due to growing recognition that financial difficulties can translate into poorer physical health states. Financial toxicity can be a risk factor for several negative oncological outcomes including worsened symptoms 15 , heightened emotional and psychological distress 16, 17 , decreased QoL 18, 19 and even increased risk of death 20 . The causal link between financial strain and worse outcomes is poorly studied, although several hypotheses have been presented. Practically, patients experiencing financial hardship are less likely to adhere to prescribed treatments and follow-up monitoring, which could result in increased rates of cancer relapse and death [21] [22] [23] . These findings are particularly true for patients who receive oral medications. Interestingly, data from preclinical models suggest that psychological stress can promote tumour growth, invasion and metastasis through stress hormone and possibly immune-mediated effects [24] [25] [26] [27] . For example, cortisol and its metabolite, cortisone, can promote androgen-independent growth of prostate cancer cells in vitro 25 . Other data suggest that chronic stress increases tissue catecholamines, which in turn stimulate β-adrenergic receptor pathways to increase tumour angiogenesis and malignant behaviour [26] [27] [28] . Another possibility is that the stress associated with financial hardship can promote telomere shortening 29 , which has been associated with prostate cancer tumorigenesis 30 . Further research is still needed to better understand these relationships.
Patients are also growing increasingly concerned about cancer's financial effects and want to discuss these with their health-care providers 31 . A review of 12 different studies of cost discussions between oncology patients and their physicians found that, on average, 60% of patients had a positive attitude towards cost discussions 32 . As these conversations are still non-standardized, many patients feel that the current level of physician engagement is inadequate 33 . The review found that despite positive attitudes, in general, fewer than one-third of study participants had actually discussed costs with their oncologist 32 .
In prostate cancer, several factors can cause considerable financial toxicity. First, changing practice patterns and modern modalities, such as robotic surgery 34 and proton therapy 35 , are increasing care costs from a societal perspective 11 . How these costs are being shifted to patients is unclear but we can speculate that individual responsibilities might be rising. During the past decade, many private US insurers have increased their use of strategies to share costs with patients, for example through deductibles, co-payments and co-insurance 36 . Approvals of expensive novel oral hormonal agents, such as abiraterone, enzalutamide and apalutamide over the same period of time, as well as possible use of these medications in high-risk localized disease, might also contribute to overall increasing costs 37 . Second, the high worldwide prevalence and specific epidemiology of prostate cancer means that many men with low baseline socioeconomic resources face the disease. These men are predisposed to developing financial toxicity owing to reduced economic reserves. The financial burden is compounded by the fact that patients with poor
Key points
• The term financial toxicity broadly reflects the financial consequences and subjective burden resulting from a cancer diagnosis and treatment. • Financial toxicity is increasingly recognized in oncology but has been poorly studied in the context of prostate cancer. • a high risk of developing financial distress might influence a patient's treatment decisions; however, no guidelines recommend explicit discussion of this topic. • a patient's risk of developing financial toxicity is multifactorial and is likely to be influenced by direct costs, indirect costs, patient-specific values and expectations of possible financial burdens, as well as individual economic circumstances. • The risk of developing financial toxicity probably differs depending on the treatment approach: surgery might particularly influence short-term risk and radiotherapy might influence long-term risk. • The overall risk of financial toxicity might be lower for men with prostate cancer than for men with other cancers; however, men with persistent treatment-related adverse effects are likely to be at higher risk.
Deductibles
The total out-of-pocket annual health-care expenses that patients must accrue before the insurance coverage activates and the payor begins to pay some (or all) of the remaining costs for that calendar year (usually a fixed annual monetary amount; for example $1,000).
Co-payments
fixed, out-of-pocket monetary amounts that patients are required to pay by their insurer for a particular health-care service such as a physician visit or a prescription drug.
Co-insurance
The amount of a total health-care cost that patients are responsible for paying after they have met their deductible (usually a fixed percentage; for example, 20%); the payor will pay the remaining portion of the cost. socioeconomic status might have increased direct and indirect health-care costs, as they are more likely to be diagnosed with high-stage disease and might have poor disease-specific outcomes 38 . Third, a unique aspect of prostate cancer is that most men are cured of their disease; however, treatment-related adverse effects, such as urinary incontinence and erectile dysfunction, can result in ongoing, associated medical costs for more than a decade 39 . Finally, many men are diagnosed while they are employed, which can result in workplace disruptions and prolonged opportunity costs. In this case, opportunity costs reflect the lost wages or decreased productivity that a man might experience due to missed work owing to primary cancer treatment or ongoing symptoms after treatment 40, 41 . Although a comprehensive economic evaluation would also consider the lost productivity from prostate cancer on a societal level, we chose to limit our focus on the effects to the per-patient level. As these problems are likely to continue to grow, this Review summarizes current knowledge of the risks of financial toxicity in patients with localized prostate cancer. The decision to concentrate on localized disease was made for several reasons. Many patients with localized disease face a treatment choice and only limited data exist on the role of patient-level costs in this decision making. Once prostate cancer is metastatic, the choice is usually removed and the current standard of care consists of continuous systemic agents, including antiandrogens and/or chemotherapies 4 . It is well established that OOP costs for expensive novel agents such as these are rising 42 . Furthermore, we hypothesize that the risks of financial toxicity for men with metastatic prostate cancer are likely to be similar to those for patients with other metastatic solid tumours, which have been better studied 43 .
We first propose a framework of several factors that seem to contribute generally to the risk of a patient with cancer developing financial toxicity. This structure guides our discussion of several emerging strategies to measure financial toxicity to help inform future research efforts in prostate cancer. We then use this framework to synthesize existing literature on localized prostate cancer, highlighting deficiencies when appropriate. Our focus is on non-metastatic prostate cancer, but we occasionally refer to studies of other cancer histologies or advanced stage disease to highlight important concepts.
A framework for evaluating financial toxicity Prognosticating a patient's risk of financial toxicity is challenging for providers, as this assessment is inherently subjective and highly individualized. Studies across cancer types have identified several broad risk factors for financial strain, including female gender, young age, low baseline income, adjuvant therapies and recent diagnosis 14 , but several of these factors are of limited relevance in prostate cancer owing to the epidemiology and treatment paradigm of this disease.
One study linked data from the Surveillance, Epidemiology, and End Results (SEER) Program of individuals diagnosed with cancer with bankruptcy records and found that, after propensity score matching, patients who declared bankruptcy had a significantly higher adjusted hazard ratio for mortality (HR 1.79, 95% CI 1.64-1.96; P < 0.001) 20 . Notably, mortality differed by cancer histology and prostate cancer was one of the strongest predictors of bankruptcy-associated mortality risk. In men with localized or regional prostate cancer who declared bankruptcy within a year of diagnosis, the adjusted mortality hazard ratio was 1.98 (95% CI 1. 25-3.15 ; P = 0.004). These findings highlight the importance of identifying patients with prostate cancer under financial strain, as the health-care team might have opportunities to assist these individuals and modify their mortality risk.
A patient's report of financial toxicity is an expression of their perceived overall effect of several complex factors, for which we propose the financial toxicity framework ( fig. 1 ), which has five components: direct costs, indirect costs, patient-specific values, expectations of possible financial burdens and individual economic circumstances.
Direct costs are the patient's OOP responsibilities owing to prostate cancer, including insurance co-payments, co-insurance and deductibles for medical visits, diagnostics, treatments, supportive care medications and follow-up care. Most of these costs (particularly shortly after treatment) are therapy-related (medical) but numerous non-medical costs also exist, such as costs of travel and parking or additional family care expenses. Direct medical costs are a function of the billed costs of required treatments, medications or services excluding what the patient's insurance will pay. For health-care systems with private insurance, the net sum that a patient might ultimately owe is based on the patient's primary insurance structure and extent of member cost-sharing and availability of supplemental insurance. For patients whose insurance plans have annual deductibles (which are increasingly common in the USA), medical expenses previously accrued in that calendar year (regardless of disease) also count towards the OOP cost burden.
Indirect costs are the opportunity costs of prostate cancer, such as lost income due to a patient's and/or spouse's inability to work or a decrease in productivity. Any lost salary from premature mortality can also be considered 44 .
Patient-specific values are a patient's personal preferences and perceptions, which influence how they react to medical-related expenses and are the most difficult contributors to generalize. For some individuals, continuation of treatment and/or maximization of curative potential are paramount even if associated with a 
Opportunity costs
The financial or other benefits a person misses out on by choosing one alternative over another (in the context of working, opportunity costs could reflect the lost wages from days not worked owing to illness).
Member cost-sharing
features of insurance plans that are designed to distribute some of the fees billed for health care to beneficiaries (for example, deductibles, co-payments and co-insurance models).
Supplemental insurance
extra or additional insurance that a person can obtain to cover some of the out-of-pocket health-care expenses not covered by the primary insurance plan.
www.nature.com/nrurol substantial financial burden. For example, a survey of 300 insured patients with solid tumours (non-prostate) revealed that nearly 50% were willing to declare personal bankruptcy to receive care 45 . For others, treatment preferences are guided by different priorities, such as physician recommendation, avoidance of particular adverse effects, or minimizing time away from employment 7 . Incongruity between a patient's values and that patient's selected treatment might increase the possibility of a negative impression of the treatment-related cost, but this hypothesis requires further study. Expectations of possible financial burdens reflect both a man's knowledge and perception of the economic effect that a prostate cancer diagnosis will have on his family. A critical component is whether somebody from the care team has provided the patient with an accurate estimate of the potential on-treatment and post-treatment costs he might face. The patient then assesses how these potential direct and indirect costs balance with current and future family assets. Anticipatory guidance on the possibility of considerable medical costs can lessen negative psychological effects 46 . Effective communication between patients and physicians or other members of the care team (for example, financial counsellors) is an important component of setting expectations. Patients might be reticent to discuss cost concerns with their oncologist, particularly in time-constrained appointments. The prevalence of patient-physician cost conversations regarding prostate cancer treatments is unknown, but findings of a survey of physicians caring for patients with localized breast cancer suggest that these discussions do not occur routinely: 51% of medical oncologists, 16% of surgeons and 43% of radiation oncologists report that their office 'often' or 'always' discusses financial burden with patients 33 . A study of 300 patients with non-prostate cancers of whom 21.7% had localized disease found that, even after adjusting for financial burden as a share of income (required, as cost was assessed as a respondent's best estimate of recent average monthly OOP expense), unexpected costs are associated with increased financial distress (OR 4.78, 95% CI 2.02-11.32; P < 0.01) and with reduced willingness to pay (OR 0.48, 95% CI 0.25-0.95; P = 0.03) 47 . Patients are increasingly requesting more robust cost discussions during up-front treatment decision making 32, 33, 48, 49 .
Individual economic circumstances, which include a patient's baseline wealth, pre-existing debts and economic reserve, are key factors that might influence eventual toxicity. For example, US$1,000 in unplanned medical cost could be catastrophic to certain patients but negligible to others. Providers should be encouraged to consider the possibility of financial distress broadly, as the group of patients with prostate cancer who feel subjectively burdened by cost might be socioeconomically heterogeneous 50 . Studies of patients with other cancers have demonstrated that insured patients remain at risk of financial strain 21 and a risk of under-insurance exists (defined as spending >10% of income on health-care costs) 47 .
Of note, methodologies for studying these factors are highly heterogeneous. Financial toxicity can be evaluated using top-down or bottom-up approaches ( fig. 1 ). A bottom-up approach considers and weighs some, or all, of the five aforementioned factors to evaluate predisposition to financial toxicity. By contrast, a top-down approach considers the final synthesis: does a patient report subjective distress or do subjective or objective indicators of distress exist? Many studies have hybrid designs that include components of both analytical techniques.
Strategies to assess financial toxicity
Given the complexity of factors that can contribute to financial toxicity and how it can be studied, the diversity and number of outcome metrics and patient tools to help researchers assess a patient's risk of financial toxicity is unsurprising ( fig. 2 ). Considerable heterogeneity exists in how these potential outcomes have been interpreted and reported 14 . The most appropriate outcome or analytical tool depends on the specific research goal. For example, efforts to better understand total direct costs might involve the auditing of patients' cancer-associated payments over a given period but this audit alone would be unsatisfactory to assess financial toxicity, as it omits numerous other components. By contrast, studies using a top-down strategy might choose a different analytical approach and quantify objective implications of financial strain (for example, patients' declarations of bankruptcy) or screen patients holistically for subjective financial stress. Owing to little uniformity in early patient-level financial outcomes, the development of objective, patient-reported financial toxicity screening instruments has been a valuable addition to homogenize the field's research methods 51, 52 . The Comprehensive Score for Financial Toxicity (COST) is an assessment of patient financial strain on the basis of 11 questions each with a five-point Likert scale 51 . COST is becoming popular as a preferred screening tool in financial toxicity research and has been proposed as a standardized instrument in future studies 14 . COST was validated in patients with advanced-stage, metastatic cancers receiving systemic therapies 53, 54 , so its applicability to patients with localized prostate cancer is unclear; to our knowledge, its performance has not been specifically studied in patients with localized prostate cancer but we anticipate that such data will be forthcoming. Another utilized tool is the InCharge Financial Distress/Financial Well-Being Scale (IFDFW) 52 . IFDFW is an eight-question, Likert-scale-based tool but contains more general financial questions and does not have any specific mention of cancer or disease.
To date, screening tools such as COST have been mainly used in research but data from these tools are likely to be increasingly incorporated into clinical practice. Prostate cancer specialists already have much experience collecting and tracking patient-reported QoL metrics (for example, urinary, bowel or sexual function), so inclusion of an additional tool should affect clinical workflows only minimally. However, predictions of how this information will influence clinical practice or treatment recommendations would currently be premature.
Applying the financial toxicity framework
The framework for evaluating risk of cancer-associated financial toxicity focuses on men with localized prostate cancer, as greater attention has already been paid to the prevalence and risk of financial toxicity in patients
Likert scale
A psychometric tool frequently used in surveys that ask respondents to state their level of agreement or frequency using predefined criteria (for example, agree, strongly agree, etc.). naTure revIewS | Urology R e v i e w s volume 17 | January 2020 | 31 with advanced or metastatic cancers. Each domain in the framework also serves as a possible area for clinicians to provide anticipatory guidance or intervention.
Direct costs Prostate cancer treatment options and their costs.
Annual US-wide prostate cancer expenditure is rising, and is projected to reach $15-20 billion by 2020 (ref. 55 ). Listed prices for medical services typically reflect costs billed to payors or directly to uninsured patients. Rates of uninsured patients are projected to rise after repeal of the US individual insurance mandate, which was part of the Affordable Care Act and required US citizens to obtain health insurance 56 (Box 1). Owing to the repeal of this mandate effective in 2019, more men might become uninsured and could face catastrophic financial burdens if diagnosed with prostate cancer requiring immediate treatment. These prices are typically inflated compared with the actual resource-derived economic costs 57 or the amounts that are ultimately reimbursed, which are usually negotiated downward as part of contracting processes between hospitals and payors.
The average listed prices (that is, for an uninsured patient) of a radical prostatectomy procedure vary widely across the USA: for example, in 2014, mean hospital fees were $34,720 ($10,000-135,000; s.d. $20,335) 58 . Estimates for physician and anaesthetic fees are lower, averaging at >$8,000 ($4,028-18,720; s.d. $4,282) 58 .
For patients who choose radiotherapy, the two main treatment modalities are EBRT or brachytherapy. EBRT options include a traditional treatment course over ~9 weeks or moderately hypofractionated EBRT delivered over ~4-5 weeks 4 . Additionally, ultra-hypofractionated EBRT regimens, such as stereotactic body radiotherapy (SBRT), which are completed in five or fewer treatments, are becoming more accepted in the USA as an approach for select patients 59 . Finally, proton therapy, which typically involves a longer treatment course than SBRT, is also an option and potentially has a lower risk of treatment-related adverse effects 60, 61 . A national commercial claims database study found that from a payor's perspective, mean radiotherapy costs were $49,504, $57,244 and $115,501 for SBRT, a traditional 9-week course of EBRT, and a standard course of proton beam therapy, respectively. Costs were estimated and averaged from insurance claims made between 2008 and 2015 and presented as adjusted 2015 US dollars 60 .
Brachytherapy involves surgical implantation of radioactive seeds (low dose-rate brachytherapy), or catheters for delivery of radioactive isotopes (high dose-rate brachytherapy) focally to the prostate gland in one to four treatments 62 . Medicare reimbursements in 2014 were ~$10,000 for low dose-rate brachytherapy and $10,000-20,000 for high dose-rate brachytherapy 63 .
Estimating direct medical costs faced by US patients.
Both prostate surgery and radiotherapy are expensive, definitive therapies and no contemporary benchmarks exist for how US insurers currently share these costs with patients. However, nationally, medical costs in general have risen and are increasingly shifted to patients in the form of more deductibles, co-insurance and co-payments 64 . The Kaiser Family Foundation estimated that in 2017, for inpatient hospital admissions, 64% of covered workers have some degree of co-insurance (at an average rate of 19%) and 12% have co-payments, 10% have per diem hospital payments, 6% have co-payment and co-insurance and 17% have no additional cost sharing assuming the general annual deductible has been met 64 . These data suggest that even insured patients possibly face substantial short-term OOP costs. Assuming $20,000 in reimbursement for a prostatectomy procedure has been negotiated by a hospital with an insurer, the average patient with co-insurance could be billed $3,800 (19% of the total reimbursement). Extended courses of radiotherapy might increase patient OOP cost burdens, as patients are typically billed for weekly status checks with their radiation oncologist. Only a few efforts have been made to benchmark patients' specific monetary responsibilities following treatment for localized prostate cancer but these estimates were prepared before the US Affordable Care Act came into law so probably underestimate contemporary obligations.
In a qualitative research study in 2012, Jung et al. 50 evaluated 41 men with clinically localized prostate cancer treated with prostatectomy (56%) or EBRT (39%) in the preceding 6-18 months at a US academic medical centre. Nearly all patients had employer-sponsored insurance (68%) or Medicare (17%) and patients recalled a median OOP expense during the preceding 12 months of $640 (interquartile range $270-1,500). These costs were incurred for treatment-related deductibles and co-payments for treatment, supplies, medications and laboratory tests.
In a larger study, 2008-2012 Medical expenditure Panel Survey data were used to assess excess self-reported direct medical expenditure by 1,170 survivors of prostate cancer 65 . The researchers found that, compared with age-matched controls without a cancer diagnosis, survivors of prostate cancer had significantly higher incremental adjusted annual medical costs (non-elderly (18-64 years of age) population $3,586, 95% CI $1,792-6,076; elderly (>65 years of age) population $3,524, 95% CI $1,539-5,909). The amount of direct costs remained relatively consistent across ages for patients with prostate cancer, but significant differences existed compared with survivors of other common cancers. For non-elderly patients, direct costs for survivors of prostate cancer were 30% lower than those for survivors of breast cancer (mean $5,119, 95% CI $3,439-7,158, P < 0.001) and 59% lower than those for survivors of colorectal cancer (mean $8,647, 95% CI $4,932-13,974, P < 0.001). For elderly patients, direct costs for survivors of prostate cancer were 29% lower than those for survivors of colorectal cancer (mean $4,913, 95% CI $2,768-7,470) but 54% greater than those for survivors of breast cancer (mean $2,288, 95% CI $814-$3,995).
In a cross-sectional study from 2010 of patients treated between 2005 and 2008 including 427 patients with prostate cancer (77% with early-stage disease) of whom ~75% had been treated within the preceding 2 years, 18% of respondents reported OOP expenses since diagnosis of $2,500-5,000 and 20% of respondents reported >$5,000 (2008 US dollars) 66 .
The only prospective direct cost estimate comes from a cohort study of 512 patients with newly diagnosed, localized prostate cancer treated between 2002 and 2005 at either an urban academic centre or a Veterans Affairs hospital 41 . Patients (69% radical prostatectomy and 31% EBRT) completed surveys at baseline and at 3, 6, 12 and 24 months of follow-up to estimate direct and indirect OOP costs for patients and caregivers. The OOP cost estimates are limited as the researchers did not specifically ask about costs of non-covered outpatient or inpatient care. Their survey assessed costs of medications and several non-medical direct costs, including transportation, parking, meals and supplemental care-giving expenses. After prostatectomy and after EBRT, mean total OOP costs were <$1,000 (in 2009 US dollars) at 3, 6, 12 and 24 months of follow-up; however, the patterns of cost differed between the two treatments. OOP costs after prostatectomy rose in the short term and then stabilized, whereas EBRT-associated costs were initially lower but rose in the long term, probably reflecting patterns of adverse effects of these treatments. For example, at 3 months after treatment, mean total OOP costs were $781 (standard error (s.e.) $2,284) for prostatectomy and $532 (s.e. $2,973) for EBRT 41 . For prostatectomy, the mean costs fell to ~$400 and remained constant at 6, 12 and 24 months. Mean OOP costs at 1 year and 2 years after EBRT were $587 (s.e. $1,891) and $661 (s.e. $2,036), respectively. After propensity score correction, initial costs were higher for prostatectomy than for EBRT but surgery was also associated with lower total costs and lower medication costs. No differences were found in indirect costs or non-medical costs between these treatments 41 .
A patient's insurance status will strongly influence their OOP cost burden. For example, an observational study comparing OOP health-care expenditures for Medicare beneficiaries between 1997 and 2007 with and without cancer (including 401 patients with prostate cancer) concluded that patients with cancer faced nearly $1,000 more (in 2007 US dollars) in adjusted, annual incremental OOP spending than those without cancer 67 . For beneficiaries with cancer, the median and mean total OOP cost burden as a share of annual income were 10% and 24%, respectively, suggesting that some beneficiaries have much higher OOP cost burdens than others. The presence of supplemental insurance outside primary Medicare (P < 0.01) as well as a higher income (>200% of federal poverty line; P < 0.01) were significant protectors against large OOP cost burdens (defined as >20% of annual income). Greater assets, comorbid conditions and receipt of radiotherapy or antineoplastic treatments were associated with a greater hazard of a large OOP cost burden.
To our knowledge, no contemporary estimates exist for the cost to the patient of medications including Affordable Care Act Also known as the ACA, PPACA or obamacare. A comprehensive US healthcare reform law passed in 2010 that contained several provisions, including the requirement that US citizens obtain health insurance or face a tax (known as the individual mandate).
Medical Expenditure Panel Survey
A set of US-wide surveys of individuals and families, their medical providers, and employers, providing one of the most complete data sources for the cost and use of health care and health insurance coverage in the USA.
Box 1 | The US Affordable Care Act and potential financial toxicity implications
In response to rising national health-care expenditures and uninsured rates, the affordable Care act (aCa, also known as PPaCa) was signed into law in the uSa in 2010 (ref. 101 ). The aCa was a pivotal attempt at health-care policy reform and created a mandate for uS citizens to have health insurance (or face a tax). It also removed the ability of private payors to deny insurance coverage to patients with considerable pre-existing medical conditions. many uS payors then found themselves mandated to provide coverage to an expanded group of 'high-risk' individuals who had the potential to be substantial utilizers of health-care services (and therefore insurance). In response, many insurers adopted more cost-sharing mechanisms for all their beneficiaries, such as deductibles and co-insurance, as a way to offset this new risk. many employers, who often provide their workers with health insurance, also faced rising premiums and, in turn, used cost sharing to pass along some of this additional cost to employees 102 . after the aCa was passed into law, insurance coverage increased on a national level; however on a patient level, out of pocket (ooP) costs also often increased 64 . as a result, the prevalence and degree of patient financial toxicity likely increased for most uS citizens (even those who had previously been insured), owing to increased direct costs as well as stress related to a higher than expected financial burden associated with health care. Predicting the trend for cost sharing (and therefore patient ooP cost burden) going forward is more challenging because, since 2019, the tax penalty for individuals who choose not to purchase insurance has been reduced to $0, effectively eliminating the individual insurance mandate.
androgen-deprivation therapy or oral agents to address the adverse effects of therapy (such as, alpha antagonists or anticholinergics). Given that patients might require these medications for prolonged periods of time, the financial burden can compound.
International estimates of direct costs to the patient of prostate cancer.
Global heterogeneity of health-care systems and reimbursement models make it difficult to draw comparisons between countries; however, comparing the patterns of cost can provide some insight. Presumably, patients' objective OOP cost burdens should be lower in countries with greater health-care access and medical expense coverage.
In a cross-sectional study, Gordon et al. 68 surveyed 289 Australian men recruited electronically from prostate cancer support groups in 2013 for their self-reported OOP costs of a diagnosis of prostate cancer associated with treatment, changes in employment status and household finances. Most men had been diagnosed in the preceding 5 years (65%) and underwent prostatectomy (69%). Metastatic disease developed in 20% of respondents. The reported median total OOP expenditure since diagnosis was AUD$8,000 (interquartile range $14,000; 2012 Australian dollars). The distribution of OOP costs was strongly skewed to increased costs and 5% of patients reported OOP costs of >AUD$30,000. Of note, health care in Australia is a mixed system of public and private providers with most care being provided publicly; respondents with private insurance reported double the OOP costs of those with public insurance. The authors speculated that this difference was due to several factors, including consumerism influencing prostate cancer treatment choices and that, although many Australian private insurers might have a low premium, they are usually more restrictive in the services they cover and often subject patients to numerous, open-ended co-payments 68 .
Health-care systems such as the Canadian model in which medical costs are usually comprehensively reimbursed also highlight additional direct cost considerations. A Canadian study of 170 patients with prostate cancer treated between 2008 and 2009 considered OOP costs on a granular level 69 . Although <20% of men incurred significant OOP expenses (defined as >7.5% of quarterly income), men with greater overall OOP cost burden had above average travel costs. The reasons for this finding were not explicitly discussed but it might have been due to the regionalization of specialized cancer centres in Canada.
The magnitude of the direct OOP costs must be interpreted in the patient's broader financial context. A cross-sectional study of survivors of prostate and breast cancer from the National Cancer Registry Ireland found that men with prostate cancer had a significantly higher risk of cancer-related financial stress than patients with breast cancer (breast cancer relative risk 0.78, 95% CI 0.63-0.96; P = 0.019) 70 . Increased risk of stress was associated with the presence of pre-diagnosis financial stress, presence of mortgage or personal financial obligations, increased direct OOP costs, increased household expenses and having dependents. Ireland has a complex mixed public-private health-care system with universal coverage, but most individuals must pay fees for medical services and prescription drugs.
Direct costs: summary and open questions.
Despite ample data on the costs of various treatment modalities at the payor level, few robust estimates exist of patient-level direct cost burden after prostate cancer treatment. Differences in the methodologies and time periods of data collection, as well as heterogeneity of health-care systems, further complicate aggregated assessments. However, these data reasonably lead to the conclusion that men can face total OOP cost burdens of several thousand dollars following treatment with the potential for substantially larger sums. Patterns of OOP cost can be different according to treatment modality: several reports suggest that the bulk of the cost for both surgical and radiotherapeutic management occurs in the first year, but patients undergoing prostatectomy tend to have higher total costs in the immediate postoperative period owing to the need for early interventions and a concentrated period of work loss. Radiotherapy-related OOP costs might initially be lower but seem to rise during the first 2 years after treatment, reflective of the time course of adverse effects or the differing demographics of men undergoing radiotherapy (that is, older patients with generally higher medical costs). Additional studies to validate these findings in the contemporary insurance environment are needed, to better enable clinicians or staff to provide evidence-based OOP cost estimates to patients. Ideally, these studies should be prospective and linked to financial toxicity screening instruments such as COST 51 .
Indirect costs
Defining indirect costs. Indirect costs are the monetary value assigned to time spent receiving medical care, time recovering from illness or time lost due to premature death 55 . These costs aim to reflect lost 'opportunity' and as these events are, by definition, not realized, indirect costs are always estimated. Indirect costs affect patients as well as care-giving family members and can be substantial. Indirect costs have several components, including monetary losses due to workplace absenteeism, reduced productivity due to presenteeism (working while impaired owing to cancer), and lost income due to early retirement or cancer-related death.
Of note, although routine PSA screening remains controversial, if clinicians follow the AUA guideline of shared decision making regarding screening starting at age 55 years 71 , a considerable proportion of men diagnosed with prostate cancer are likely to be fully employed. Recovery from treatment and associated adverse effects are well known to affect the ability to work of individuals with cancer 72 but studies specifically in prostate cancer are limited, especially in the USA.
Effect of post-treatment employment disruptions.
Several studies have attempted to quantify changes in survivors' employment status following prostate cancer treatment and some have used this information to estimate indirect cost burden. An analysis using propensity
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www.nature.com/nrurol score matching in 267 patients with prostate cancer (aged 30-65 years; 75% with local disease) and two population-based control groups of 283 and 256 men without prostate cancer found that men with cancer were significantly less likely to be working 6 months after diagnosis 73 . Overall, men with prostate cancer were 10% (95% CI 3-18%) less likely to be working; patients treated with surgery were 17% (95% CI 8-25%) and those treated with chemotherapy or radiotherapy (groups not separated) were 11% (95% CI 4-25%) less likely to be working 73 . Notably, the difference in employment status between patients and men without prostate cancer was not significant by 12 months after treatment but around one-quarter of men (26%, 95% CI 18.5-33.9%) reported cancer-associated difficulties with tasks that required physical effort. Furthermore, 16% of men (95% CI 9.7-21.4%) with prostate cancer felt they could not keep pace at work. Finally, they were significantly more likely to retire from their job than controls (at 12 months 11% versus 1%, P < 0.001).
However, not all studies found significant effects on employment. The analysis of data from 1,170 survivors of prostate cancer in the 2008-2012 Medical Expenditure Panel survey showed a more modest effect of treatment on employment losses 65 . Non-elderly (aged 18-64 years) survivors of prostate cancer reported significant but relatively small excess missed days of work compared with age-matched and sex-matched controls without prostate cancer (mean 2.7 days, 95% CI 1.1-5.1 days), which translated into a modest reduction in per capita productivity of $271 (95% CI $110-511). Compared with controls, survivors of prostate cancer did not have significantly increased amounts of disability time or days spent at home, both of which were significantly increased for survivors of colorectal and breast cancer.
To assess prostate-cancer associated indirect costs, most studies have adopted a human capital approach that assumes that lost earnings are a proxy for lost output and generally multiplies incremental time lost from employment by wage per unit time 74 . Although this method is commonly adopted, a potential concern is that, from an economics perspective, a patient's absenteeism might reflect personal lost earnings but that loss does not usually translate into overall market productivity losses. The prospective study in 512 patients with newly diagnosed, localized prostate cancer used human capital methods to estimate indirect cost differences at various time points following prostatectomy or radiotherapy 41 . Indirect costs are most prevalent in the first year after treatment and tend to be initially higher for patients who have undergone prostatectomy but, overall, are similar to patients who receive radiotherapy. For example, log linear regression analysis found that, compared with EBRT, prostatectomy overall did not have greater odds of indirect costs (OR 0.69, 95% CI 0.62-1.8) but the odds were significantly greater at 3 months after treatment (OR 4.1, 95% CI 3.0-4.2) 41 . Increased cost estimates for patients who have undergone prostatectomy are principally driven by more hours of missed work. In this study, at 3 months after treatment, men recovering from prostatectomy reported missing 139 h of work (s.e. 221 h) compared with 62 h (s.e. 215 h) for men recovering from EBRT 41 .
These data support the hypothesis that younger patients have greater opportunity cost for prostate cancer treatment because they are more likely to be employed and also more likely to be working full time than elderly men. A survey of individuals on the SEER registry suggests that men diagnosed with prostate cancer missed an average of 27 days of work in the 6 months after diagnosis, and those treated with hormone therapy and/or radiotherapy or who were not treated missed fewer days of work (median 3 days) than those undergoing surgery (median 25 days) 75 .
Quantifying the effect of caregiver support. The financial effect of prostate cancer is not limited to the patient. One study from 2009 used the human capital approach to quantify the value of 'informal caregiver time' , which was time not spent pursuing usual activities including work or leisure 76 . The study surveyed 688 principal patient-nominated caregivers of cancer survivors (of whom 19% had prostate cancer) between 2003 and 2006. Across the entire cohort, ~80% had localized or regional disease but how many patients with prostate cancer had metastatic disease was not reported. The study had a broad definition of care-giving, including emotional support, financial support, symptom management, personal care and transportation. In the 2 years following diagnosis, prostate cancer caregivers reported providing a mean of 12.5 months (s.d. 8 months) of support on average 9 h per day (s.d. 9 h per day); however, the frequency of support varied. Using the median national wage of 2006, the researchers estimated that the mean value of this caregiver time was ~$45,000 (95% CI $35,389-54,381) annually.
Another study used a similar human capital approach to estimate the opportunity costs associated with lost productivity of 88 partner caregivers of men with localized prostate cancer 77 . Opportunity cost was considered as reductions in the time caregivers worked and spent providing informal support. The estimated mean indirect burden at 1 year after diagnosis was ~$6,000 ($571-47,105 in 2009 US dollars).
International perspectives of indirect cost burden. The
Australian cross-sectional study by Gordon et al. 68 of 289 men also surveyed for effects on employment and found that 23% of men reported that their prostate cancer diagnosis led to early retirement (mean 4-5 years earlier than planned). Overall, 14% of men reduced their work hours as a result of their diagnosis. The opportunity costs of these employment changes were not quantified.
A group from Ontario, Canada assessed opportunity and direct OOP costs of 585 long-term survivors of prostate cancer (range 2-13 years from treatment) who presented to clinics or support groups 78 . Overall, mean indirect costs were CAD$838 per year and mean OOP costs were CAD$200 per year (in 2006 Canadian dollars). Of note, although these values are generally low, they account for ~10% of the income of patients with low earnings. Radical prostatectomy, young age, poor urinary function, current hormone therapy and recent diagnosis (using diagnosis year treated as a continuous variable as a proxy) were significantly associated with Human capital approach A commonly used labour economic strategy to estimate indirect costs that assumes that lost earnings are a proxy for lost output and generally multiplies incremental time lost from employment by wage per unit time. naTure revIewS | Urology increased likelihood of incurring total costs (sum of time costs plus direct OOP costs). The finding that indirect costs are higher than direct costs are probably a reflection of the structure of the Ontario health-care system in which all residents have government-financed health insurance for medically necessary services including prescription drugs for those >65 years of age. Many rely on supplemental private insurance to help pay for prescription drugs and health-care services, such as allied health and medical equipment. Travel and time costs (key components of indirect cost burdens) are usually covered by patients or their caregivers. This trend highlights how a country's health-care system strongly influences which driver of financial toxicity is likely to be most relevant for its patients with prostate cancer. In Europe, where most nations have some form of universal health-care coverage 79, 80 , direct costs for medical services might be a less important consideration. However, even among nations with single-payor systems, the extent of coverage and amount of services covered vary widely, necessitating nation-by-nation analysis for proper assessments of financial toxicity.
Additional drivers of indirect cost.
The indirect financial implications of a patient's treatment decision are complex and might have competing influences. For example, a 2018 National Cancer Database study showed that even when adjusted for sociodemographic and clinical factors, patients with longer travel distance to a treatment centre were more likely to receive SBRT than long-course radiotherapy 81 . The study authors provided two sound but contradictory hypotheses for this observation. First, patients with greater travel requirements have a greater risk of financial toxicity when receiving long-course radiotherapy owing to, for example, travel costs and indirect costs of missed work. Second, men who live further from the treatment centre but have better financial and other means to travel might have greater propensity to purposefully seek SBRT. Interestingly, the authors theorized that younger men who are more likely to be fully employed face the greatest difference in opportunity costs between short SBRT and long-course radiotherapy. Unlike in other cancers that predominantly affect elderly adults, the frequent diagnosis of middle-aged men (who are likely to be actively working and might be the primary provider for their family) and high cure rates of prostate cancer by either surgery or radiotherapy mean that treatment-related adverse events that impair productivity have the potential to result in substantial opportunity costs.
Indirect costs: summary and open questions.
Similar to OOP costs, the considerable heterogeneity in how indirect costs are estimated and quantified challenges the ability to generalize patterns for the average patient with prostate cancer. For example, inclusion of caregiver indirect costs has the potential to greatly affect overall family burden but this expense is not routinely assessed. Most data suggest that men have disruptions to their ability to work following treatment but estimates of the magnitude of the associated financial loss vary widely from several hundred to tens of thousands of dollars (particularly if caregiver burden is included). Some findings suggest that the patterns of indirect costs are more concentrated in non-retired men and differ by treatment type. Men recovering from prostate surgery are more likely to have short-term changes to their work attendance, whereas the subacute development of radiotherapy-associated adverse effects can cause delayed absenteeism.
Prospective intervention studies can feasibly include estimates of indirect costs 82 . Going forward, the use of a standardized measurement instrument would probably be beneficial. One possibility is the Institute for Medical Technology Assessment Productivity Cost Questionnaire (iMTA iPCQ), which is an objective tool to measure productivity losses of paid work as a result of absenteeism 83 . Although proposed as a standardized instrument to quantify opportunity costs 14 , to our knowledge, the iPCQ has not been specifically used in patients with prostate cancer.
Patient-specific values
Patient-level predictors of increased financial toxicity risk. A patient's direct and indirect costs must be interpreted using a patient's qualitative context and triggers of psychological distress. For localized prostate cancer, these are poorly categorized but a few findings suggest various possible predictors of the likelihood of a patient reporting financial distress, including low baseline socioeconomic status, being a member of certain racial minority groups and a background of less education.
The qualitative study Jung et al. 50 from 2012 using semi-structured interviews in a small cohort of 41 insured patients treated for localized prostate cancer in the preceding 6-18 months found a fairly modest proportion of patients (24%) who declared a substantial burden from their OOP financial responsibilities. One in five respondents reported a need to reduce non-medical spending or make other sacrifices to afford prostate cancer treatment. Those men who expressed greater subjective burden predominantly reported an OOP expense of ≥$1,500 over the preceding 12 months, had annual incomes of <$60,000 and were more likely to be black and be educated to below college level. These results should be interpreted in the context that this population was small and consisted of around two-thirds of white men and relatively affluent patients as 58% earned >$60,000 annually. Despite these caveats, three of nine patients who reported subjective burden had incomes of >$60,000 per year; thus, the risk of prostate cancer-related financial toxicity is probably not limited to under-represented minority groups or patients with low annual incomes. Given that the average American family has <$5,000 in a bank account 84 , the occurrence of treatment-related financial distress might be more common than most providers appreciate.
Association between financial toxicity and treatmentrelated adverse effects.
Post-treatment complications or persistent symptoms are very likely to affect a patient's risk of financial toxicity. The prospective assessment of OOP and indirect costs in a cohort of 512 patients showed that a greater total cost burden is inversely correlated with health-related QoL, including www.nature.com/nrurol prostate-specific domains, such as urinary, bowel and sexual function or bother 41 . This association is probably due to several factors, such as an increased need for physician visits and supportive care medications, and the possibility of dissatisfaction with treatment choices in the context of unanticipated adverse effects. The association is not trivial, as each of the treatment options has considerable risk of distinct QoL impairments 85 .
Furthermore, a causal link between patient-reported health-related QoL (HRQoL) and a patient's subsequent satisfaction with care has been established in newly diagnosed patients with prostate cancer. Specifically, one study, including 590 newly diagnosed US patients with prostate cancer from an urban academic hospital and a publicly funded Veterans Affairs hospital, associated patients' satisfaction with their care (assessed by CSQ-8 score) 86 with numerous HRQoL domains (assessed using the general SF-36 (ref. 87 ) and UCLA-Prostate Cancer Index 88 questionnaires) 89 . Cross-lagged correlation demonstrated that the direction of causality is from better HRQoL to overall satisfaction. Linear mixed model regression was then applied to analyse associations between different HRQoL domains and overall satisfaction and found that better reported QoL along numerous generic and prostate-specific domains (for example, physical function, role emotional, social function, general health, urinary function, bowel function, sexual function, urinary bother and bowel bother) was significantly associated with greater treatment satisfaction 89 . More simply, lower overall satisfaction with prostate cancer care tends to be a consequence of lower scores on patient-reported symptom assessment scales, such as SF-36 and UCLA-PCI. If a patient is dissatisfied with his treatment choice, he is likely to feel relatively more burdened by its financial impact.
Patient-specific values: summary and open questions.
The identification of demographic or clinical predictors of financial toxicity would be helpful to enable clinicians to give special attention to discussions with the most at-risk patients. But, even if improved estimates of possible patient-level financial burdens associated with each particular treatment option were readily available, specific OOP cost thresholds at which patients are at risk of financial toxicity can probably not be generalized. Early data suggest that financial toxicity is more prevalent in historically under-represented or disenfranchised groups (for example, men with advanced age or low socioeconomic status, or ethnic minorities) but not exclusively. Several studies have shown that even very modest OOP cost burdens can trigger financial strain. One of the more consistent findings is that persistent QoL impairments are associated with increased risk of financial toxicity. QoL can be described in many ways, but the data consistently suggest that men with sustained urinary, sexual or bowel dysfunction (either owing to or not resolved after their treatment) are at increased risk of financial distress. Causality is difficult to discern from studies with cross-sectional or even cohort designs but the drivers of this association are probably both monetary (that is, due to frequent interaction with the health-care system) and psychological due to dissatisfaction.
Expectations of possible financial burdens
Across oncology, enthusiasm is growing for increased transparency with patients regarding the costs of their care as part of shared decision making 90 . For localized prostate cancer, the joint AUA/ASTRO/SUO guideline from 2017 strongly advocates that patient counselling "should incorporate shared decision making and explicitly consider cancer severity (risk category), patient values and preferences, life expectancy, pre-treatment general functional and genitourinary symptoms, expected post-treatment functional status, and potential for salvage treatment" 91 . Although values and beliefs of patients with prostate cancer are heterogeneous, probably even a small possibility of substantial financial burden would be a concern for many people.
Urologists and radiation oncologists have been called to take a more prominent role in discussing financial topics with their patients 92 , but how often these types of conversations are occurring currently remains unclear. Evidence from studies of patients with advanced non-prostate cancers suggests that these discussions are probably infrequent. Over a decade ago, benchmarking revealed that fewer than half of 167 practising medical oncologists regularly discussed costs with their patients 93 . The clinicians cited several barriers to these discussions, including physician discomfort, lack of solutions, lack of knowledge, and uncertainty about whether the topic would be negatively perceived by the patient 93 . A study from 2017 that analysed transcriptions of 677 clinic encounters in an outpatient breast cancer clinic showed that cost conversations occurred in ~20% of encounters and 59% of the encounters were initiated by the medical oncologist 94 . These conversations lasted generally <1 min and covered a wide range of topics, including the costs of drugs and diagnostic tests.
Importantly, clinicians' potential concern that financial discussions jeopardize patient-provider relationships seems to be unfounded 95 . In a pilot study in 107 patients with metastatic breast, lung or colorectal cancer, researchers discussed potential costs associated with chemotherapy at the time of consultation. Only a minority (28%) of oncologists felt comfortable discussing costs but most patients (80%) wanted to have these conversations. Furthermore, 80% of patients had no negative feelings about hearing cost information.
Effect of patients' knowledge of potential costs on decision making.
Patients might find cost information helpful but an important question is whether these data actually influence decision making. In general, men have poor awareness of possible costs before making a treatment decision; however, this ignorance might be largely inconsequential, as patients, even those with subjective financial toxicity, tend to minimize the importance of cost when choosing a treatment. The 2012 qualitative study by Jung et al. 50 in 41 men with clinically localized prostate cancer noted poor awareness of possible OOP costs before treatment decision making. Overall, 80% of patients reported that they 'knew little' about or 'did not know' their anticipated OOP costs before choosing a specific treatment. Nevertheless, the majority of respondents (93%) in this population, naTure revIewS | Urology including most who reported high subjective financial burden, stated they would not have altered their treatment choice even if they had been better informed of the possible costs. The authors synthesized a few other themes from respondents, including that most men did not consider costs, as they felt well insured, and that treatment efficacy or the physician's recommendation should be more important than cost in making a treatment decision 50 . Interestingly, 17% of respondents felt that it was inappropriate or irrelevant for their physician to be discussing OOP costs but preferred a focus on medical topics 50 .
These results agree with the findings of the 2010 cross-sectional study of 427 patients with prostate cancer of whom most had early-stage disease: only 7% of respondents reported a 'large amount' of financial stress owing to the cost of treatment 66 . By contrast, 19%, 25% and 27% of patients with breast, colorectal or lung cancer reported a large amount of financial stress, respectively. These data suggest the interesting possibility that patients with prostate cancer are generally less prone to financial toxicity than patients with other cancers. Survivors of prostate cancer had comparatively lower OOP costs and productivity loss than survivors of other common cancers 65 . We speculate that potential explanations for the reduced financial toxicity among men with prostate cancer are that many of those diagnosed with localized disease are relatively healthy before their treatment, the incidence of severe adverse effects is overall low, oral anticancer agents were historically used comparatively rarely and a behavioural reticence of men to admit financial distress. Although intriguing, these studies predate insurers' substantial shifts of cost burden to patients; thus, their contemporary interpretation is unclear. A low prevalence of prostate cancer financial toxicity would make improved benchmarking even more critical to distinguish those most at risk.
International assessment of knowledge of potential costs.
The Australian cross-sectional study by Gordon et al. 68 of 289 men with prostate cancer found that ~70% of respondents had spent more on their cancer treatment than they had expected. Overall, 20% of patients stated that the cost of treatment caused 'a great deal' of distress and unfavourable financial effects seemed to be worse in respondents who had been more recently diagnosed.
A Canadian study in 170 men with prostate cancer found that nearly 20% of surveyed patients had substantial OOP costs in the 3 months leading up to the survey date and, although these costs considerably increased stress, they did not affect treatment decisions 69 . Of note, only around a quarter of surveyed patients informed their physician about their OOP costs and 27% of patients were aware of any financial support or assistance options. These options include pharmaceutical company co-payment support for prescription drugs or extended payment plan options. Internationally, this topic is comparatively under-studied, and data are limited on how understanding of possible costs affects treatment decisions in other countries. Furthermore, given the diversity of global health-care systems, the types of financial support or assistance options which exist are heterogeneous.
Expectations of financial burdens: summary and open questions.
Patients with cancer are increasingly seeking information about the possible costs of their potential treatments and are comfortable having these conversations with their clinicians 31, 32, 93 . Clinicians have historically been reluctant to initiate these discussions for several reasons but this avoidance might soon be unacceptable to patients in an era of greater medical cost transparency. Interestingly, men might request more cost information, but some evidence suggests that these figures do not factor strongly in their prostate cancer treatment decision-making process. In addition to validating this hypothesis, further research opportunities exist including the development of strategies for effective pre-emptive communication of medical cost data with patients.
Key lessons and emerging themes
Overall, the existing literature reveals that the potential adverse effects of financial strain remain poorly studied in patients with localized prostate cancer. Increased attention to this topic across oncology is likely to result in a heightened responsibility of providers to acknowledge and address this problem proactively with patients. The success of these conversations with men facing prostate cancer treatment decisions requires more robust study of benchmarks and predictors of financial strain that are reflective of contemporary health-care systems.
Despite the low amount of available data, several early themes can help physicians in tailoring pretreatment financial counselling efforts. The potential for substantial direct and indirect cost burdens exists after both surgery and radiotherapy. Low baseline socioeconomic status before a diagnosis of prostate cancer is predictive of an increased risk of financial toxicity but is neither a universal nor the sole cause. Effective efforts to identify men at risk will probably require expanded screening methods and certainly should focus heavily on men with persistent treatment-related QoL decrements. A man's treatment modality will probably also influence which type of post-treatment screening is optimal: men who have undergone prostatectomy are likely to have a greater risk of financial toxicity in the first months after surgery, whereas those who have completed radiotherapy might have persistent risk for years.
Finally, patients with prostate cancer might have a reduced overall risk of financial toxicity compared with those who have other common cancers. Limited qualitative data from men with prostate cancer suggest that many want their decision to be agnostic concerning financial factors and do not feel particularly strained by the costs of their subsequent care. Determining whether this point of view represents a broader trend would be an important finding that certainly warrants exploration.
Conclusions
Financial toxicity is increasingly recognized as a serious potential consequence of cancer diagnosis and treatment. Increased financial strain has been associated with numerous poor prognostic factors and, therefore, might be considered similar to other treatment-related toxicities. Focusing on prostate cancer, the next steps must include prospective studies using validated tools to www.nature.com/nrurol assess the extent of financial distress and identify specific predictors of risk. These efforts would better prepare clinicians with salient messaging to engage their patients on this topic. Possible interventions to mitigate or address financial toxicity have been suggested [96] [97] [98] ; however, many pertain to rising costs of drugs or systemic therapies. Our proposed financial toxicity framework ( fig. 1 ) not only enables clinicians to methodically assess a patient's risk of financial toxicity but also suggests broad categories for intervention. Clinicians' ability to discuss potential direct costs with their patients requires the availability of clear OOP cost benchmarks or estimates anticipated for specific health-care services 97 . Currently, this information is either unavailable or difficult to collect on an individual patient level. To ameliorate potential indirect cost burden, the development of practical communication tools could be considered. For example, tools to facilitate proactive discussion between patients and their employers concerning how prostate cancer treatment might affect their future ability to work might minimize the negative effect of treatment-related workplace absenteeism (and resulting indirect costs). Some patients might be accommodated temporarily into different roles or part-time responsibilities while they recover from their treatment. Another option is that more financially prudent interventions could be considered more routinely for men who experience sustained post-treatment adverse effects (for example, tele-health appointments, bundling of visits to several medical experts on the same day and automatic referral to social work). In the USA, addressing possible financial strain caused by definitive procedural costs owing to surgery or radiotherapy might prompt more consideration of novel reimbursement schemes, such as bundled payment or episode-based payment models 99, 100 .
Similar to many other concepts in medicine, a single strategy is unlikely to be effective. Recognizing that treatment-related costs might negatively affect patient outcomes is the first step, but successful integration of tools to identify men at risk and to discuss potential solutions into an already time-constrained clinical flow will require multidisciplinary commitment. The urologist or radiation oncologist can acknowledge the risk but must work closely with nurses, social workers, patient service representatives or financial counsellors to identify and support patients who are most likely to be affected.
Bundled payment
A financial reimbursement model in which a physician or health-care system is paid a single sum for an entire episode of care, not individual sums for each specific service provided. naTure revIewS | Urology R e v i e w s volume 17 | January 2020 | 39
